These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23749904)

  • 1. Immunological characterization of glioblastoma cells for immunotherapy.
    Jung TY; Choi YD; Kim YH; Lee JJ; Kim HS; Kim JS; Kim SK; Jung S; Cho D
    Anticancer Res; 2013 Jun; 33(6):2525-33. PubMed ID: 23749904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells.
    Zhu L; Oh JM; Gangadaran P; Kalimuthu S; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
    Front Immunol; 2018; 9():824. PubMed ID: 29740437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of HLA class I molecules and MHC class I chain-related molecules A/B in K562 and K562/AO2 cell lines and their effects on cytotoxicity of NK cells].
    Mei JZ; Niu XQ; Guo KY; Zhou J; Wei HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):288-91. PubMed ID: 17493333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Branched multipeptide immunotherapy for glioblastoma using human leukocyte antigen-A*0201-restricted cytotoxic T-lymphocyte epitopes from ERBB2, BIRC5 and CD99.
    Kim YH; Tran TA; Lee HJ; Jung SI; Lee JJ; Jang WY; Moon KS; Kim IY; Jung S; Jung TY
    Oncotarget; 2016 Aug; 7(31):50535-50547. PubMed ID: 27409668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
    Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human U87 glioblastoma cells with stemness features display enhanced sensitivity to natural killer cell cytotoxicity through altered expression of NKG2D ligand.
    Oh SJ; Yang JI; Kim O; Ahn EJ; Kang WD; Lee JH; Moon KS; Lee KH; Cho D
    Cancer Cell Int; 2017; 17():22. PubMed ID: 28203118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
    Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
    Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
    Höring E; Podlech O; Silkenstedt B; Rota IA; Adamopoulou E; Naumann U
    Anticancer Res; 2013 Apr; 33(4):1351-60. PubMed ID: 23564772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
    Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
    Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of HLA a*0201 glioblastoma multiforme cell lines for immunotherapy by PCR-SSP and DNA sequencing.
    Wu AH; Hall WA; Low WC
    J Neurooncol; 2004 Jan; 66(1-2):1-8. PubMed ID: 15015764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
    Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
    J Immunol; 2012 Mar; 188(5):2136-45. PubMed ID: 22301547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15.
    Gong W; Xiao W; Hu M; Weng X; Qian L; Pan X; Ji M
    Tissue Antigens; 2010 Dec; 76(6):467-75. PubMed ID: 20670353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.
    Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L
    Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming.
    Zhu L; Kalimuthu S; Oh JM; Gangadaran P; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
    Biomaterials; 2019 Jan; 190-191():38-50. PubMed ID: 30391801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
    Song H; Kim J; Cosman D; Choi I
    Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells.
    Wolpert F; Happold C; Reifenberger G; Florea AM; Deenen R; Roth P; Neidert MC; Lamszus K; Westphal M; Weller M; Eisele G
    PLoS One; 2015; 10(10):e0139603. PubMed ID: 26441059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.
    Lapteva N; Durett AG; Sun J; Rollins LA; Huye LL; Fang J; Dandekar V; Mei Z; Jackson K; Vera J; Ando J; Ngo MC; Coustan-Smith E; Campana D; Szmania S; Garg T; Moreno-Bost A; Vanrhee F; Gee AP; Rooney CM
    Cytotherapy; 2012 Oct; 14(9):1131-43. PubMed ID: 22900959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human T-cell leukemia virus type 1 (HTLV-1) p12I down-modulates ICAM-1 and -2 and reduces adherence of natural killer cells, thereby protecting HTLV-1-infected primary CD4+ T cells from autologous natural killer cell-mediated cytotoxicity despite the reduction of major histocompatibility complex class I molecules on infected cells.
    Banerjee P; Feuer G; Barker E
    J Virol; 2007 Sep; 81(18):9707-17. PubMed ID: 17609265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against natural killer cells by interferon-gamma treatment of K562 cells cannot be explained by augmented major histocompatibility complex class I expression.
    Nishimura M; Mitsunaga S; Akaza T; Mitomi Y; Tadokoro K; Juji T
    Immunology; 1994 Sep; 83(1):75-80. PubMed ID: 7821970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Ohno T
    J Hematother; 1999 Feb; 8(1):29-37. PubMed ID: 10192299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.